BIO-UV Group (ALTUV) Stock Overview
Designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALTUV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BIO-UV Group S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.31 |
| 52 Week High | €2.12 |
| 52 Week Low | €1.28 |
| Beta | 0.23 |
| 1 Month Change | -11.81% |
| 3 Month Change | -16.73% |
| 1 Year Change | -36.52% |
| 3 Year Change | -74.18% |
| 5 Year Change | -78.94% |
| Change since IPO | -65.95% |
Recent News & Updates
BIO-UV Group (EPA:ALTUV) Strong Profits May Be Masking Some Underlying Issues
Sep 26
BIO-UV Group S.A. (EPA:ALTUV) Looks Just Right With A 27% Price Jump
May 27Recent updates
BIO-UV Group (EPA:ALTUV) Strong Profits May Be Masking Some Underlying Issues
Sep 26BIO-UV Group S.A. (EPA:ALTUV) Looks Just Right With A 27% Price Jump
May 27With BIO-UV Group S.A. (EPA:ALTUV) It Looks Like You'll Get What You Pay For
Nov 27We Think BIO-UV Group (EPA:ALTUV) Is Taking Some Risk With Its Debt
Jun 18Returns On Capital Are Showing Encouraging Signs At BIO-UV Group (EPA:ALTUV)
Mar 16Is There An Opportunity With BIO-UV Group S.A.'s (EPA:ALTUV) 48% Undervaluation?
Dec 02BIO-UV Group (EPA:ALTUV) Is Doing The Right Things To Multiply Its Share Price
Jun 10Need To Know: Analysts Just Made A Substantial Cut To Their BIO-UV Group S.A. (EPA:ALTUV) Estimates
Apr 09Investors Still Waiting For A Pull Back In BIO-UV Group S.A. (EPA:ALTUV)
Jun 16The Return Trends At BIO-UV Group (EPA:ALTUV) Look Promising
Feb 25BIO-UV Group's (EPA:ALTUV) Earnings Are Weaker Than They Seem
Sep 30Returns At BIO-UV Group (EPA:ALTUV) Are On The Way Up
May 22Investors Who Bought BIO-UV Group (EPA:ALTUV) Shares A Year Ago Are Now Up 87%
Jan 11
Is BIO-UV Group S.A. (EPA:ALTUV) Trading At A 48% Discount?
Nov 18Shareholder Returns
| ALTUV | FR Machinery | FR Market | |
|---|---|---|---|
| 7D | -0.2% | 0.7% | 0.1% |
| 1Y | -36.5% | 33.0% | -1.3% |
Return vs Industry: ALTUV underperformed the French Machinery industry which returned 33% over the past year.
Return vs Market: ALTUV underperformed the French Market which returned -1.4% over the past year.
Price Volatility
| ALTUV volatility | |
|---|---|
| ALTUV Average Weekly Movement | 2.9% |
| Machinery Industry Average Movement | 4.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.0% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALTUV has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALTUV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 147 | Laurent-Emmanuel Migeon | www.bio-uv.com |
BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through Products, Solutions, and After-Sales divisions. The company offers disinfection equipment and systems under the triogen, AKERON, 1001 Electrodes, and BIOSEA brands; spare parts; and commissioning services.
BIO-UV Group S.A. Fundamentals Summary
| ALTUV fundamental statistics | |
|---|---|
| Market cap | €18.24m |
| Earnings (TTM) | €996.77k |
| Revenue (TTM) | €37.21m |
Is ALTUV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTUV income statement (TTM) | |
|---|---|
| Revenue | €37.21m |
| Cost of Revenue | €13.92m |
| Gross Profit | €23.29m |
| Other Expenses | €22.29m |
| Earnings | €996.77k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.072 |
| Gross Margin | 62.59% |
| Net Profit Margin | 2.68% |
| Debt/Equity Ratio | 44.1% |
How did ALTUV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 01:55 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIO-UV Group S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephanie Lefebvre | Gilbert Dupont |
| Martin Tessier | Stifel, Equities Research |